Patents by Inventor Erwin Bischoff

Erwin Bischoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130059844
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Application
    Filed: March 26, 2012
    Publication date: March 7, 2013
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jorg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • Publication number: 20110009367
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Application
    Filed: March 4, 2010
    Publication date: January 13, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Maria Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • Patent number: 7704999
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: April 27, 2010
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Maria Niewöhner, legal representative, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • Patent number: 7696206
    Abstract: The application claims a compound of the formula or a salt, a hydrate, or a hydrate of a salt thereof. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of erectile dysfunction.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: April 13, 2010
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Maria Niewöhner, legal representative, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jorg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • Publication number: 20100016323
    Abstract: The application claims a compound of the formula or a salt, a hydrate, or a hydrate of a salt thereof. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of erectile dysfunction.
    Type: Application
    Filed: September 29, 2009
    Publication date: January 21, 2010
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Ulrich Niewöhner, Maria Niewöhner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • Publication number: 20090221570
    Abstract: The present invention relates to the use of PDE 5 inhibitors generally and in particular of known 2-phenyl-substituted imidazotriazinone derivatives for manufacturing medicaments for the treatment of pathological states which can be treated by raising cGMP levels in certain tissues, such as, for example, of, for example: primary pulmonary hypertension, secondary pulmonary hypertension, pulmonary arterial hypertension, portopulmonary hypertension, hepatopulmonary syndrome, pulmonary hypertension caused by medicaments (amphetamines), interstitial lung disease, pulmonary hypertension occurring with HIV, thromboembolic pulmonary hypertension, pulmonary hypertension in children and neonates, pulmonary hypertension induced by atmospheric hypoxia (altitude sickness), COPD, emphysema, chronic bronchial asthma, mucoviscidosis-related pulmonary hypertension, right heart failure, left heart failure and global failure, and which can be treated by raising cGMP levels in certain tissues, such as, for example, isolated syst
    Type: Application
    Filed: March 27, 2006
    Publication date: September 3, 2009
    Applicant: Bayer Helthcare AG
    Inventors: Helmut Haning, Peter Serno, Erwin Bischoff, Ernst Ulbrich
  • Publication number: 20080113972
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Application
    Filed: December 21, 2007
    Publication date: May 15, 2008
    Applicant: Bayer Aktiengesellschaft
    Inventors: Ulrich Niewohner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jorg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski, Maria Niewohner
  • Publication number: 20080096880
    Abstract: The invention relates to novel uses of imidazo[1,2,4]triazinones for producing a medicament for the treatment and/or prophylaxis of coronary cardiopathy, heart failure, pulmonary hypertension, bladder complaints, prostatic hyperplasia, nitrate-induced tolerance, or diseases of the eye, such as glaucoma, for the treatment or prophylaxis of central, retinal or posterior ciliary artery occlusion, central retinal vein occlusion, optical neuropathy, such as anterior ischaemic optical neuropathy and glaucomatous optical neuropathy, in addition to macular degeneration, diabetes, in particular diabetic gastroparesis, for the treatment of dysperistalsis of the stomach and oesophagus, female infertility, premature contractions, pre-eclampsia, alopecia, psoriasis associated with renal syndrome, cystic fibrosis, cancer and for improving cognition, powers of concentration, learning skills or hypermnesia, in particular if the disorder is a symptom of dementia.
    Type: Application
    Filed: June 24, 2003
    Publication date: April 24, 2008
    Applicant: Bayer Heakthcare AG
    Inventors: Helmut Haning, Erwin Bischoff, Ulrich Niewohner, Maria Niewohner
  • Publication number: 20080085897
    Abstract: The present invention relates to the use of known 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position and cGMP PDE-inhibitory properties for the treatment of cardiac insufficiency, cancer, bladder disorders, or prostate hyperplasia.
    Type: Application
    Filed: October 1, 2007
    Publication date: April 10, 2008
    Applicant: Bayer HealthCare AG
    Inventors: Ulrich Niewohner, Maria Niewohner, Erwin Bischoff, Helmut Haning, Afssaneh Rahbar, Tiemo-Joerg Bandel, Wolfgang Barth
  • Patent number: 7314871
    Abstract: The application claims a method for treating hypertension by administering an effective amount of a compound of the formula (I) wherein the variable groups are as defined in the specification and claims. These 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: January 1, 2008
    Assignee: Bayer Aktiengesellschaft
    Inventors: Maria Niewöhner, legal representative, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski, Ulrich Niewöhner, deceased
  • Patent number: 7276504
    Abstract: The present invention relates to the use of known 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position and cGMP PDE-inhibitory properties for the production of medicaments for the treatment of cardiac insufficiency, psoriasis, female infertility, cancer, diabetes, ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: October 2, 2007
    Assignee: Bayer HealthCare AG
    Inventors: Maria Theresia Niewohner, legal representative, Erwin Bischoff, Helmut Haning, Afssaneh Rahbar, Tiemo-Joerg Bandel, Wolfgang Barth, Ulrich Niewohner, deceased
  • Patent number: 7173037
    Abstract: The present invention relates to compounds which stimulate soluble guanylate cyclase, to the preparation thereof and to the use thereof as medicaments, in particular as medicaments for the treatment of cardiovascular disorders and/or sexual dysfunction.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: February 6, 2007
    Assignee: Bayer HealthCare AG
    Inventors: Cristina Alonso-Alija, Erwin Bischoff, Klaus Münter, Johannes-Peter Stasch, Elke Stahl, Stefan Weigand, Achim Feurer
  • Patent number: 7135474
    Abstract: This application relates to compounds of the formula (I) in which R1 is chlorine, cyano, trifluoromethyl or methoxy and R2 is hydrogen or flurorine; or R1 and R2 are both fluorine; and to pharmaceutically acceptable salts of these materials. Pharmaceutical compositions containing these materials, and methods of using them in treatment of hypertension and sexual dysfunction are also disclosed and claimed.
    Type: Grant
    Filed: May 5, 2003
    Date of Patent: November 14, 2006
    Assignee: Bayer Healthcare AG
    Inventors: Stefan Weigand, Erwin Bischoff, Klaus Münter, Johannes-Peter Stasch, Elke Stahl
  • Patent number: 7122540
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: October 17, 2006
    Assignee: Bayer HealthCare AG
    Inventors: Maria Niewöhner, legal representative, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Semo, Marc Nowakowski, Ulrich Niewöhner, deceased
  • Patent number: 7098207
    Abstract: Novel imidazotriazinones of general formula a method for the production and the pharmaceutical use thereof are disclosed.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: August 29, 2006
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Maria Niewohner, legal representative, Mazen Es-Sayed, Thomas Lampe, Helmut Haning, Gunter Schmidt, Karl-Heinz Schlemmer, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn, Ulrich Niewohner, deceased
  • Publication number: 20060189615
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Application
    Filed: April 21, 2006
    Publication date: August 24, 2006
    Applicant: Bayer Aktiengesellschaft
    Inventors: Ulrich Niewohner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jorg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski
  • Publication number: 20060189624
    Abstract: Disclosed is a combination preparation for the treatment of sexual dysfunction in men or women containing at least one active ingredient A and one active ingredient B as pharmaceutically active ingredients, whereby the active ingredient A is a PDE inhibitor, preferably a cGMP PDE inhibitor and the active ingredient B a lipid-reducing agent. Both the active ingredients A and B can be administered simultaneously or at alternate intervals, that is, as a functional unit or separated from each other.
    Type: Application
    Filed: February 3, 2006
    Publication date: August 24, 2006
    Applicant: Bayer Aktiengesellschaft
    Inventors: Erwin Bischoff, Hilmar Bischoff, Francois Giuliano
  • Patent number: 7091203
    Abstract: The invention relates to imidazo[1,3,5]triazinones, a method for their production and methods of use, in particular as inhibitors of cyclic GMP metabolizing phosphodiesterases.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: August 15, 2006
    Assignee: Bayer Healthcare AG
    Inventors: Ulrich Niewöhner, Helmut Haning, Thomas Lampe, Mazen Es-Sayed, Gunter Schmidt, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn, Karl-Heinz Schlemmer
  • Publication number: 20060160810
    Abstract: The 2-phenyl-substituted imidazotriazinones having short unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolising phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for treating cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for treating erectile dysfunction.
    Type: Application
    Filed: February 4, 2002
    Publication date: July 20, 2006
    Inventors: Ulrich Niewohner, Maria Niewohner, Helmut Haning, Martin Radtke, Dietrich Seidel, Erwin Bischoff, Wolfgang Karl
  • Patent number: 7074780
    Abstract: The present invention relates to substituted phenylcyclohexanecarboxamides of the formula (I) to processes for their preparation and to their use in medicaments, in particular for the prevention and/or treatment of cardiovascular disorders.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: July 11, 2006
    Assignee: Bayer Aktiengesellschaft
    Inventors: Erwin Bischoff, Thomas Krahn, Stephan-Nicholas Müller, Holger Paulsen, Joachim Schuhmacher, Henning Steinhagen, Wolfgang Thielemann